The MARCOPOLO study of ustekinumab utilization and efficacy in a real-world setting

Treatment of patients with plaque psoriasis in Asia-pacific countries

Sang Woong Youn, Tsen Fang Tsai, Colin Theng, Siew Eng Choon, Benny E. Wiryadi, Antonio Pires, Weihao Tan, Mingeol Lee

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Ustekinumab is a fully human monoclonal antibody approved for the treatment of chronic moderate-to-severe plaque psoriasis in adults. However, factors including efficacy, tolerability, ease of use, and cost burden may affect ustekinumab utilization. Noncompliance may, in turn, affect treatment response. Objective: To evaluate ustekinumab utilization in the real-world setting in Asia-Pacific countries. Methods: In this phase 4 observational study conducted in Indonesia, Malaysia, Singapore, Korea, and Taiwan, adults with plaque psoriasis receiving ustekinumab were followed for up to 52 weeks. Study endpoints were the proportion of all patients using ustekinumab according to label-recommended intervals and the proportion of Korean patients who achieved a psoriasis area severity index 75 response at week 16. Safety was assessed by monitoring adverse events. Results: Overall, 169 patients received ustekinumab (Korea, n=102; other countries, n=67). Just over half (56.2%) of patients used ustekinumab with the label-recommended interval from baseline to week 40; the proportion was higher in Korea (73.5%) than in other countries (29.9%), probably because ustekinumab was provided without charge for Korean patients up to week 40. Noncompliance increased after week 40 in Korea and from week 28 in other Asia-Pacific countries, with cost cited as the most common reason. At week 16, 56.9% of Korean patients achieved a Psoriasis Area Severity Index 75 response. Safety results were in line with those seen in previous studies. Conclusion: More than half of all patients in Asia-Pacific countries used ustekinumab as per the label-recommended dose interval, but reimbursement variations between countries may have confounded overall results.

Original languageEnglish
Pages (from-to)222-231
Number of pages10
JournalAnnals of Dermatology
Volume28
Issue number2
DOIs
Publication statusPublished - 2016 Apr 1

Fingerprint

Psoriasis
Korea
Therapeutics
Safety
Ustekinumab
Costs and Cost Analysis
Indonesia
Malaysia
Singapore
Taiwan
Observational Studies
Monoclonal Antibodies

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Youn, Sang Woong ; Tsai, Tsen Fang ; Theng, Colin ; Choon, Siew Eng ; Wiryadi, Benny E. ; Pires, Antonio ; Tan, Weihao ; Lee, Mingeol. / The MARCOPOLO study of ustekinumab utilization and efficacy in a real-world setting : Treatment of patients with plaque psoriasis in Asia-pacific countries. In: Annals of Dermatology. 2016 ; Vol. 28, No. 2. pp. 222-231.
@article{2668e40d3efc4088bd792ff17ca849b6,
title = "The MARCOPOLO study of ustekinumab utilization and efficacy in a real-world setting: Treatment of patients with plaque psoriasis in Asia-pacific countries",
abstract = "Background: Ustekinumab is a fully human monoclonal antibody approved for the treatment of chronic moderate-to-severe plaque psoriasis in adults. However, factors including efficacy, tolerability, ease of use, and cost burden may affect ustekinumab utilization. Noncompliance may, in turn, affect treatment response. Objective: To evaluate ustekinumab utilization in the real-world setting in Asia-Pacific countries. Methods: In this phase 4 observational study conducted in Indonesia, Malaysia, Singapore, Korea, and Taiwan, adults with plaque psoriasis receiving ustekinumab were followed for up to 52 weeks. Study endpoints were the proportion of all patients using ustekinumab according to label-recommended intervals and the proportion of Korean patients who achieved a psoriasis area severity index 75 response at week 16. Safety was assessed by monitoring adverse events. Results: Overall, 169 patients received ustekinumab (Korea, n=102; other countries, n=67). Just over half (56.2{\%}) of patients used ustekinumab with the label-recommended interval from baseline to week 40; the proportion was higher in Korea (73.5{\%}) than in other countries (29.9{\%}), probably because ustekinumab was provided without charge for Korean patients up to week 40. Noncompliance increased after week 40 in Korea and from week 28 in other Asia-Pacific countries, with cost cited as the most common reason. At week 16, 56.9{\%} of Korean patients achieved a Psoriasis Area Severity Index 75 response. Safety results were in line with those seen in previous studies. Conclusion: More than half of all patients in Asia-Pacific countries used ustekinumab as per the label-recommended dose interval, but reimbursement variations between countries may have confounded overall results.",
author = "Youn, {Sang Woong} and Tsai, {Tsen Fang} and Colin Theng and Choon, {Siew Eng} and Wiryadi, {Benny E.} and Antonio Pires and Weihao Tan and Mingeol Lee",
year = "2016",
month = "4",
day = "1",
doi = "10.5021/ad.2016.28.2.222",
language = "English",
volume = "28",
pages = "222--231",
journal = "Annals of Dermatology",
issn = "1013-9087",
publisher = "Korean Dermatological Association",
number = "2",

}

The MARCOPOLO study of ustekinumab utilization and efficacy in a real-world setting : Treatment of patients with plaque psoriasis in Asia-pacific countries. / Youn, Sang Woong; Tsai, Tsen Fang; Theng, Colin; Choon, Siew Eng; Wiryadi, Benny E.; Pires, Antonio; Tan, Weihao; Lee, Mingeol.

In: Annals of Dermatology, Vol. 28, No. 2, 01.04.2016, p. 222-231.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The MARCOPOLO study of ustekinumab utilization and efficacy in a real-world setting

T2 - Treatment of patients with plaque psoriasis in Asia-pacific countries

AU - Youn, Sang Woong

AU - Tsai, Tsen Fang

AU - Theng, Colin

AU - Choon, Siew Eng

AU - Wiryadi, Benny E.

AU - Pires, Antonio

AU - Tan, Weihao

AU - Lee, Mingeol

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Background: Ustekinumab is a fully human monoclonal antibody approved for the treatment of chronic moderate-to-severe plaque psoriasis in adults. However, factors including efficacy, tolerability, ease of use, and cost burden may affect ustekinumab utilization. Noncompliance may, in turn, affect treatment response. Objective: To evaluate ustekinumab utilization in the real-world setting in Asia-Pacific countries. Methods: In this phase 4 observational study conducted in Indonesia, Malaysia, Singapore, Korea, and Taiwan, adults with plaque psoriasis receiving ustekinumab were followed for up to 52 weeks. Study endpoints were the proportion of all patients using ustekinumab according to label-recommended intervals and the proportion of Korean patients who achieved a psoriasis area severity index 75 response at week 16. Safety was assessed by monitoring adverse events. Results: Overall, 169 patients received ustekinumab (Korea, n=102; other countries, n=67). Just over half (56.2%) of patients used ustekinumab with the label-recommended interval from baseline to week 40; the proportion was higher in Korea (73.5%) than in other countries (29.9%), probably because ustekinumab was provided without charge for Korean patients up to week 40. Noncompliance increased after week 40 in Korea and from week 28 in other Asia-Pacific countries, with cost cited as the most common reason. At week 16, 56.9% of Korean patients achieved a Psoriasis Area Severity Index 75 response. Safety results were in line with those seen in previous studies. Conclusion: More than half of all patients in Asia-Pacific countries used ustekinumab as per the label-recommended dose interval, but reimbursement variations between countries may have confounded overall results.

AB - Background: Ustekinumab is a fully human monoclonal antibody approved for the treatment of chronic moderate-to-severe plaque psoriasis in adults. However, factors including efficacy, tolerability, ease of use, and cost burden may affect ustekinumab utilization. Noncompliance may, in turn, affect treatment response. Objective: To evaluate ustekinumab utilization in the real-world setting in Asia-Pacific countries. Methods: In this phase 4 observational study conducted in Indonesia, Malaysia, Singapore, Korea, and Taiwan, adults with plaque psoriasis receiving ustekinumab were followed for up to 52 weeks. Study endpoints were the proportion of all patients using ustekinumab according to label-recommended intervals and the proportion of Korean patients who achieved a psoriasis area severity index 75 response at week 16. Safety was assessed by monitoring adverse events. Results: Overall, 169 patients received ustekinumab (Korea, n=102; other countries, n=67). Just over half (56.2%) of patients used ustekinumab with the label-recommended interval from baseline to week 40; the proportion was higher in Korea (73.5%) than in other countries (29.9%), probably because ustekinumab was provided without charge for Korean patients up to week 40. Noncompliance increased after week 40 in Korea and from week 28 in other Asia-Pacific countries, with cost cited as the most common reason. At week 16, 56.9% of Korean patients achieved a Psoriasis Area Severity Index 75 response. Safety results were in line with those seen in previous studies. Conclusion: More than half of all patients in Asia-Pacific countries used ustekinumab as per the label-recommended dose interval, but reimbursement variations between countries may have confounded overall results.

UR - http://www.scopus.com/inward/record.url?scp=84963512342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963512342&partnerID=8YFLogxK

U2 - 10.5021/ad.2016.28.2.222

DO - 10.5021/ad.2016.28.2.222

M3 - Article

VL - 28

SP - 222

EP - 231

JO - Annals of Dermatology

JF - Annals of Dermatology

SN - 1013-9087

IS - 2

ER -